Palatin Technologies

Melanocortin-pathway therapeutics

PTN · NYSE · United States

Share price · PTN

$5.15-5.36 (-51.00%) 3M

close as of 2026-11-18 · 24h delayed · vol 11K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PTN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 15 Oct 2026-12.5%
  2. 16 Sep 2026-13.5%
  3. 15 Sep 2026-18.1%
  4. 1 Sep 2026+15.5%
  5. 12 Aug 2026+27.8%
  6. 29 Jun 2026-9.6%
  7. 15 Jun 2026-8.2%
  8. 13 May 2026-16.0%
  9. 9 Dec 2025+28.6%
  10. 4 Dec 2025+28.6%

Share of unusual movement by asset

For each asset, the share of PTN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
bremelanotide (Vyleesi)
events and moves
6shown from 8 days
PL9643
events and moves
4shown from 8 days
PL8177
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—4%
Other company news (earnings, financing, releases naming no asset)—30%
Sessions with no dated event—67%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
Melanocortin receptorsPeptide
Dry Eye Disease
bremelanotide(Vyleesi)
Phase 2
MC4RPeptide
Obesity
Phase 2
MC1RPeptide
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 March 2025Topline resultbremelanotideBMT-801 Phase 2 obesity co-administration study meets primary endpoint
28 March 2025Topline resultPL8177Palatin reports Phase 2 topline results for oral PL8177 in ulcerative colitis
Palatin Technologies · Source ↗
Q1 2025Topline resultbremelanotidePhase 2 of bremelanotide with tirzepatide met its primary endpoint
28 February 2024Topline resultPL9643MELODY-1 Phase 3 misses planned co-primary endpoints
Palatin Technologies · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
FY2026-Q3$3.9M$3.5M$10M$4.4Mreport ↗

Palatin Technologies reported revenue of $3.92M for FY2026 Q3, up from zero YoY, reflecting collaboration and license revenue. R&D spend was $3.52M, down 6.4% YoY, and cash and equivalents totaled $10.16M. The company recorded a net loss of $1.43M for the quarter, with a quarterly net burn of $4.4M.

The company highlighted its melanocortin receptor platform, including Boehringer Ingelheim’s August 2025 acquisition of certain Palatin intellectual property, and projected IND filings for its obesity program: a once-weekly MC4R agonist in Q4 calendar 2026 and an oral small-molecule MC4R agonist in 1H calendar 2027. PL8177, an oral MC1R formulation for ulcerative colitis, reported positive topline Phase 2 data in Q1 2025, and an MCR agonist for diabetic nephropathy reported positive topline data in Q4 2024. Management stated that existing cash is expected to fund operations through the next twelve months.

View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$3.5M$10M$1.4M-$4.4M operating cash flowreport ↗
2025-Q4—$4.3M$14M$7.3M-$4.8M operating cash flowreport ↗
2025-Q3$8.8M$2.5M$1.3M—-$1.6M operating cash flowreport ↗
2025-Q1$0$3.8M$2.5M$4.8M-$5.3M operating cash flowreport ↗
2024-Q4—$3.4M$3.4M$2.4M-$4.8M operating cash flowreport ↗
2024-Q3$0$5.7M$2.4M$7.8M-$7.0M operating cash flowreport ↗
2024-Q1$0$7.2M$10M+ $0 short-term inv.$8.4M-$8.6M operating cash flowreport ↗
2023-Q4$2.0M$5.5M$9.5M+ $0 short-term inv.$7.8M-$10M operating cash flowreport ↗
2023-Q3$2.1M$5.0M$5.5M+ $0 short-term inv.$5.9M-$5.9M operating cash flowreport ↗
2023-Q1$1.2M$4.8M$20M$7.2M-$1.4M operating cash flowreport ↗
2022-Q4$1.0M$4.4M$21M$1.4M-$17M operating cash flowreport ↗
2022-Q3$0.9M$6.0M$21M$8.3M-<$0.1M operating cash flowreport ↗
2022-Q1$0.2M$5.0M$38M$7.6M-$9.5M operating cash flowreport ↗
2021-Q4$0.3M$5.4M$47M$8.7M-$6.3M operating cash flowreport ↗
2021-Q3$0.2M$3.5M$53M$7.1M-$6.4M operating cash flowreport ↗

Annual history (6 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$8.8M$12M$7.5M$2.1M-$14M operating cash flowreport ↗
View 5 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$15M$2.6M$4.3M-$21M operating cash flowreport ↗
2024-FY$4.5M$22M$9.5M+ $0 short-term inv.$7.4M-$31M operating cash flowreport ↗
2023-FY$4.8M$23M$8.0M+ $3.0M short-term inv.$6.9M-$28M operating cash flowreport ↗
2022-FY$1.5M$21M$30M+ $0 short-term inv.$9.1M<$0.1M operating cash flowreport ↗
2021-FY-$0.2M$13M$60M$8.4M-$23M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($9K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-03PRENDERGAST JOHN K A · directorCode Z (derivative)2,900——Form 4
2026-08-03DUNTON ALAN W · directorCode Z (derivative)2,200——Form 4
2026-08-03Morris Arlene · directorCode Z (derivative)2,400——Form 4
2026-07-15WILLS STEPHEN T · Executive VP and CFO/COOTax withholding22$11.77$259Form 4
2026-07-15SPANA CARL · director, President and CEOTax withholding33$11.77$388Form 4
2026-07-15WILLS STEPHEN T · Executive VP and CFO/COOTax withholding79$11.72$926Form 4
2026-07-15SPANA CARL · director, President and CEOTax withholding119$11.72$1KForm 4
2026-07-15WILLS STEPHEN T · Executive VP and CFO/COOTax withholding94$14.34$1KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 26 reporting institutions held 0.8M shares ($13.4M, 43.3% of shares outstanding).

#InstitutionSharesValue
1Driehaus Capital Management LLC166,713$2.9M
2JANUS HENDERSON GROUP PLC140,000$2.4M
3Logos Global Management LP140,000$2.4M
4RA CAPITAL MANAGEMENT, L.P.70,000$1.2M
5PERCEPTIVE ADVISORS LLC61,945$1.1M
6Balyasny Asset Management L.P.41,169$717K
7SUPERSTRING CAPITAL MANAGEMENT LP35,969$627K
8MORGAN STANLEY27,272$475K
9VANGUARD CAPITAL MANAGEMENT LLC18,979$331K
10GEODE CAPITAL MANAGEMENT, LLC18,502$322K
11Miller Financial Services LLC12,600$219K
12LPL Financial LLC12,555$219K
13CITADEL ADVISORS LLC11,091$193K
14VANGUARD FIDUCIARY TRUST CO8,774$153K
15UBS Group AG3,329$58K